Your SlideShare is downloading. ×
PharmaPoint: Meningococcal Vaccines - Global Drug Forecast and Market Analysis to 2022
PharmaPoint: Meningococcal Vaccines - Global Drug Forecast and Market Analysis to 2022
PharmaPoint: Meningococcal Vaccines - Global Drug Forecast and Market Analysis to 2022
PharmaPoint: Meningococcal Vaccines - Global Drug Forecast and Market Analysis to 2022
PharmaPoint: Meningococcal Vaccines - Global Drug Forecast and Market Analysis to 2022
PharmaPoint: Meningococcal Vaccines - Global Drug Forecast and Market Analysis to 2022
PharmaPoint: Meningococcal Vaccines - Global Drug Forecast and Market Analysis to 2022
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

PharmaPoint: Meningococcal Vaccines - Global Drug Forecast and Market Analysis to 2022

78

Published on

Meningococcal disease is an acute infection caused by the gram-negative bacterium Neisseria meningitidis. Its rapid onset and severity of symptoms makes prompt and effective diagnosis and treatment …

Meningococcal disease is an acute infection caused by the gram-negative bacterium Neisseria meningitidis. Its rapid onset and severity of symptoms makes prompt and effective diagnosis and treatment nearly impossible. For these reasons the meningococcal disease space is dominated by vaccines. Currently, tetravalent conjugate vaccines, such as Sanofi’s Menactra and Novartis’ Menveo, account for the vast majority of global sales, with the US adolescent market being the key target segment.

Published in: Business, Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
78
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
1
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. PharmaPoint: Meningococcal Vaccines - Global Drug Forecast and Market Analysis to 2022Meningococcal disease is an acute infection caused by the gram-negative bacterium Neisseria meningitidis.Its rapid onset and severity of symptoms makes prompt and effective diagnosis and treatment nearlyimpossible. For these reasons the meningococcal disease space is dominated by vaccines. Currently,tetravalent conjugate vaccines, such as Sanofi’s Menactra and Novartis’ Menveo, account forthe vast majority of global sales, with the US adolescent market being the key target segment.GlobalData expects growth in the meningococcal vaccines market to be primarily driven by the launch ofserotype B vaccines, which address a critical unmet need in the treatment landscape. Vaccines that betterprotect infants and/or provide a longer duration of immunity also have an opportunity to seize market shareduring 2012-2022.ScopeOverview of meningococcal disease, including epidemiology, etiology, general symptoms from infection,and national vaccination recommendations and guidelines. Annualized meningococcal vaccine marketrevenue, annual cost of vaccination and treatment usage pattern data from 2012 and forecast for ten years to2022. Key topics covered include strategic competitor assessment, market characterization, unmet needs,clinical trial mapping and implications for the meningococcal vaccine market. Pipeline analysis:comprehensive data split across different phases and emerging trends, specifically serotype B vaccines andearly stage infant and pentavalent vaccines. Analysis of the current and future market competition in the globalmeningococcal vaccine market. Insightful review of the key industry and governmental drivers, restraints andchallenges. Each trend is independently researched to provide qualitative analysis of its implications.Market Model FeaturesAn interactive excel forecast model based on primary research interviews and surveys with KOLs andhigh-prescribing physicians is included in this report*. This patient based model provides diagnosis rates,patient segmentation, treatment rates, annual costs of therapy , and indication-specific drug sales for the 10year forecast period. The forecast model is robust, fully transparent, and easy to navigate. Moreover, ourmodels support data presented in the reports and the complete methodology is outlined in the report and themodel.*Model only available with site and global license purchases.Key FindingsCountry-specific epidemiology and serotype distributions heavily influence immunization recommendationsand vaccine usage. Serotype B vaccines are expected to drive growth of the market space during the forecastperiod. Major players will leverage their R&D, manufacturing, and distribution networks to maintain theirstakes in the market. Government endorsements of new and existing vaccines are anticipated to dramaticallyinfluence market growth. Key Questions Answered in this ReportHow large an impact will serotype B vaccines have on the meningococcal market? What do key opinionleaders think of these vaccines? What are the key vaccines for each age segment and country? Whichmeningococcal vaccines will face adoption challenges in the market? What is the projected uptake of newvaccines, such as Novartis’ Bexsero, over the forecast period? The developmental pipeline consists ofvaccines that address serotype B protection and immunogenicity in infants. Which of these vaccines will attainPharmaPoint: Meningococcal Vaccines - Global Drug Forecast and Market Analysis to 2022
  • 2. high sales revenues during 2012-2022 and in which markets? What governmental and industry developmentsare likely to affect the vaccination rates in the markets researched? Which is the largest growth marketglobally?Key Benefits Develop and design your in-licensing and out-licensing strategies through a review of pipelineproducts and technologies, and by identifying the companies with the most robust pipeline. Develop businessstrategies by understanding the trends shaping and driving the meningococcal vaccine market. Drive revenuesby understanding the key trends, innovative products and technologies, market segments, and companieslikely to impact the global meningococcal vaccine market in future. Formulate effective sales and marketingstrategies by understanding the competitive landscape and by analyzing the performance of variouscompetitors. Identify emerging players with potentially strong product portfolios and create effectivecounter-strategies to gain a competitive advantage. Track drug sales in the global meningococcal vaccinemarket from 2012-2022. Organize your sales and marketing efforts by identifying the market categories andsegments that present maximum opportunities for consolidations, investments and strategic partnerships.table Of Contents1table Of Contents21.1list Of Tables81.2list Of Figures112meningococcal Vaccines: Executive Summary122.1meningococcal Vaccine Sales Expected To Grow During The Forecast Period132.2vaccine Manufacturers Concentrate On Unexploited Segments Of The Market, As Exemplified BySerogroup B Vaccine Development142.3healthcare Providers Clamor For Cost-effective Vaccines That Provide Broader Serogroup Coverage152.4serogroup B Vaccines Are Primed For Strong Market Debuts By Offering Unprecedented SerogroupCoverage162.5serogroup B Vaccines Will Stimulate Robust Growth In The Meningococcal Vaccines Market162.6what Do The Physicians Think?173introduction193.1catalyst193.2related Reports193.3upcoming Related Reports194disease Overview214.1etiology And Pathophysiology214.1.1etiology214.1.2pathophysiology23PharmaPoint: Meningococcal Vaccines - Global Drug Forecast and Market Analysis to 2022
  • 3. 4.2symptoms234.3prognosis245epidemiology255.1disease Background255.2risk Factors And Co-morbidities255.2.1infants And Young Children Are At Greatest Risk For Developing Meningococcal Disease265.2.2direct Contact And Overcrowding Are The Primary Risk Factors For Infection265.2.3exposure Is Highest For Those Traveling To The African “meningitis Belt”275.3global Trends285.3.1us285.3.25eu285.3.3australia295.3.4brazil305.4forecast Methodology305.4.1sources Used315.4.2forecast Assumptions And Methods345.4.3sources Not Used375.5epidemiology Forecast Of Meningococcal Disease (2012-2022)375.5.1incident Cases Of Meningococcal Disease375.5.2age-specific Incident Cases Of Meningococcal Disease395.5.3incident Cases Of Meningococcal Disease By Serogroup415.6discussion435.6.1conclusions On Epidemiological Trends435.6.2limitations Of The Analysis445.6.3strengths Of The Analysis446disease Management466.1meningococcal Immunization Policy466.2us486.2.1meningococcal Immunization Recommendations And Policies486.2.2clinical Practice496.3france516.3.1meningococcal Immunization Recommendations And Policies516.3.2clinical Practice526.4germany536.4.1meningococcal Immunization Recommendations And Policies536.4.2clinical Practice546.5italy546.5.1meningococcal Immunization Recommendations And Policies546.5.2clinical Practice55PharmaPoint: Meningococcal Vaccines - Global Drug Forecast and Market Analysis to 2022
  • 4. 6.6spain556.6.1meningococcal Immunization Recommendations And Policies556.6.2clinical Practice566.7uk576.7.1meningococcal Immunization Recommendations And Policies576.7.2clinical Practice586.8japan596.8.1meningococcal Immunization Recommendations And Policies596.8.2clinical Practice596.9australia606.9.1meningococcal Immunization Recommendations And Policies606.9.2clinical Practice616.10brazil626.10.1meningococcal Immunization Recommendations And Policies626.10.2clinical Practice627competitive Assessment647.1overview647.2strategic Competitor Assessment647.3product Profiles – Major Brands657.3.1menactra657.3.2menveo697.3.3nimenrix727.3.4menhibrix757.3.5menitorix787.3.6meningitec817.3.7menjugate847.3.8neisvac-c867.3.9menomune897.3.10bexsero938opportunity And Unmet Need978.1overview978.2unmet Needs978.2.1unmet Need: Protection Against Serogroup B Disease978.2.2unmet Need: A Pentavalent (menabcwy) Vaccine988.2.3unmet Need: More Cost-effective Vaccines998.2.4unmet Need: Improved Duration Of Immunity In Children And Adolescents998.2.5unmet Need: Immunogenic Infant Vaccines1008.2.6unmet Need: Improved Vaccination Coverage Rates1018.2.7unmet Need: Increased Patient Awareness And Education102PharmaPoint: Meningococcal Vaccines - Global Drug Forecast and Market Analysis to 2022
  • 5. 8.3unmet Needs Gap Analysis1028.4opportunities1038.4.1opportunity: Broadening Serogroup Protection With New And Existing Antigen Combinations1038.4.2opportunity: Improving Immune Response Duration With Adjuvants1038.4.3opportunity: Developing More Cost-effective Vaccines By Partnering With Manufacturers In EmergingMarkets1049pipeline Assessment1059.1overview1059.2clinical Trial Mapping1059.2.1clinical Trials By Country1059.3clinical Trials By Phase And Trial Status1079.4promising Vaccines In Clinical Development1089.4.1mnb Rlp20861109.5promising Vaccines In Early Clinical Development1149.5.1meninge Acyw Conj.1149.5.2menabcwy1179.5.3menc Conjugate1199.5.4heptavalent Dtp-hib-hepb-ipv-menc12110current And Future Players12310.1overview12310.2trends In Corporate Strategy12510.3company Profiles12610.3.1sanofi12610.3.2novartis12910.3.3glaxosmithkline13110.3.4baxter13310.3.5nuron Biotech13410.3.6pfizer13611market Outlook13811.1global Markets13811.1.1forecast13811.1.2drivers And Barriers – Global Issues14011.2united States14311.2.1forecast14311.2.2key Events14511.2.3drivers And Barriers14611.3france149PharmaPoint: Meningococcal Vaccines - Global Drug Forecast and Market Analysis to 2022
  • 6. 11.3.1forecast14911.3.2key Events15111.3.3drivers And Barriers15211.4germany15311.4.1forecast15311.4.2key Events15511.4.3drivers And Barriers15611.5italy15711.5.1forecast15711.5.2key Events15911.5.3drivers And Barriers16011.6spain16111.6.1forecast16111.6.2key Events16411.6.3drivers And Barriers16411.7united Kingdom16511.7.1forecast16511.7.2key Events16811.7.3drivers And Barriers16911.8japan17011.8.1drivers And Barriers17011.9australia17111.9.1forecast17111.9.2key Events17411.9.3drivers And Barriers17511.10brazil17611.10.1forecast17611.10.2key Events17811.10.3drivers And Barriers17912appendix18112.1bibliography18112.2abbreviations19412.3methodology19612.4forecasting Methodology19612.4.1vaccine Coverage19612.4.2vaccine Approval Vs. Routine Schedule Inclusion19712.4.3vaccines Included19712.4.4key Launch Dates19712.4.5general Pricing Assumptions19812.4.6individual Vaccine Assumptions19912.4.7pricing Of Pipeline Agents204PharmaPoint: Meningococcal Vaccines - Global Drug Forecast and Market Analysis to 2022
  • 7. 12.5physicians And Specialists Included In This Study20512.6about The Authors20812.6.1authors20812.6.2reviewers20812.6.3epidemiologists20812.6.4global Head Of Healthcare20912.7about Globaldata21012.8contact Us21012.9disclaimer210ResearchMoz(http://www.researchmoz.us/) is the one stop online destination to find and buy market researchreports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with ourhuge collection of market research reports. We provide our services to all sizes of organizations and across allindustry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well aspublishers and will assist you in making an informed decision by giving you unbiased and deep insights onwhich reports will satisfy your needs at the best price.Contact:M/s Sheela,90 State Street,Suite 700,Albany NY - 12207United StatesTel: +1-518-618-1030USA - Canada Toll Free 866-997-4948Email: sales@researchmoz.usWebsite: http://www.researchmoz.us/PharmaPoint: Meningococcal Vaccines - Global Drug Forecast and Market Analysis to 2022

×